Molecular Partners (MOLN) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Molecular Partners AG is advancing its proprietary DARPin therapeutics, with significant progress in their Radio-DARPin Therapy platform, particularly the MP0712 candidate for treating neuroendocrine tumors, set to enter clinical trials in 2025. The company has also made strides with its MP0533 therapy for acute myeloid leukemia, showing promising clinical responses, and introduced the innovative Switch-DARPin platform, showcasing a novel ‘on/off’ mechanism for targeted immune responses. Financially, Molecular Partners is well-funded into 2027, expecting operating expenses between CHF 65-75 million for the year 2024.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.